Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

1.370 -0.060 (-4.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,671
Open 1.410
Bid (Size) 1.350 (96)
Ask (Size) 1.370 (1)
Prev. Close 1.430
Today's Range 1.350 - 1.410
52wk Range 1.250 - 3.620
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-18.93%
-18.93%
1 Month
-26.74%
-26.74%
3 Month
-16.97%
-16.97%
6 Month
-30.46%
-30.46%
1 Year
-3.01%
-3.01%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
From bioAffinity Technologies, Inc.
Via Business Wire
Are Pharma Stocks Harmful To Your Financial Health ?
Via Talk Markets
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
From bioAffinity Technologies, Inc.
Via Business Wire
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024
Via InvestorPlace
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Nasdaq Tumbles 3%; US Economy Adds 114,000 Jobs In July
Via Benzinga
Topics Economy
Exposures Economy
Dow Dips Over 400 Points; Apple Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
From bioAffinity Technologies, Inc.
Via Business Wire
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024
Via InvestorPlace
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
From bioAffinity Technologies, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.